The Leukemia & Lymphoma Society (LLS) will present new data from its Beat AML® Master Clinical Trial and Pediatric Acute Leukemia (PedAL) Master Clinical Trial at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition.
The findings from LLS’s convened master clinical trials show great progress and are helping shape the treatment landscape for acute leukemias. Updated results show that more than half of a group of children with relapsed acute leukemias achieved remission after receiving a combination of treatments. Additional data indicate that IDH inhibitors as single agent or in combination with low-intensity therapies may be a viable treatment option for older adults with acute leukemias.
LLS will also support its more than 150 funded researchers, as well as more than a dozen current and former LLS Therapy Acceleration Program® (TAP) biotech company partners, who will present the latest updates from their ongoing clinical trials.
„For 75 years, LLS has funded physician-scientists and researchers who take risks, think big and test bold ideas,“ says Lee Greenberger, Ph.D., LLS’s Chief Scientific Officer. „Our strategic investments have helped advance more than 70% of blood cancer treatments approved by the FDA over the past 20 years and I am encouraged to see how the latest data at ASH will lead to remarkable advances for patients.“
Health equity is also a major focus of findings from several investigators funded through the LLS Equity in Access and IMPACT grant programs, which:
Show that there’s significant underrepresentation of women and racial and ethnic minorities in clinical trial enrollment
Provide patient recommendations on how to address disparities in people living with multiple myeloma
Share insights on how to address barriers to opening clinical trials in a community-oncology setting
Demonstrate the disparities in access to care and services depending on the type of insurance coverage.
„LLS has an incredible track record of success across its research, health equity, patient advocacy, and education and support services,“ says E. Anders Kolb, M.D., The Leukemia & Lymphoma Society’s President and CEO. „The breadth of research we support every year at ASH reinforces our commitment to improve and extend the lives of blood cancer patients and accelerate progress.“
https://ash.confex.com/ash/2024/webprogram/Paper192631.html
